These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22972444)

  • 21. Patient-reported outcomes from a 16-week open-label, multicenter study of insulin pump therapy in patients with type 2 diabetes mellitus.
    Rubin RR; Peyrot M; Chen X; Frias JP
    Diabetes Technol Ther; 2010 Nov; 12(11):901-6. PubMed ID: 20879963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The DIAB.&TE.S Project: how patients perceive diabetes and diabetes therapy.
    Marra G;
    Acta Biomed; 2004 Dec; 75(3):164-70. PubMed ID: 15796090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Insulin therapy and quality of life. A review.
    Pouwer F; Hermanns N
    Diabetes Metab Res Rev; 2009 Sep; 25 Suppl 1():S4-S10. PubMed ID: 19662621
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Identification of factors predicting early evolution of secondary oral hypoglycaemic agent failure and evaluation of clinical standards applied by primary care physicians during qualification to insulin therapy of patients with type 2 diabetes].
    Machoy M
    Ann Acad Med Stetin; 2004; 50(2):29-39. PubMed ID: 16529163
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quality of life following a change in therapy for diabetes mellitus.
    Pibernik-Okanović M; Szabo S; Metelko Z
    Pharmacoeconomics; 1998 Aug; 14(2):201-7. PubMed ID: 10186460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient Self-reported quality of life assessment in Type 2 diabetes mellitus: A pilot study.
    PrasannaKumar HR; Mahesh MG; Menon VB; Srinath KM; Shashidhara KC; Ashok P
    Niger J Clin Pract; 2018 Mar; 21(3):343-349. PubMed ID: 29519984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Knack of treatment with oral hypoglycemic drugs in the elderly].
    Komatsu M; Hashizume K
    Nihon Rinsho; 2006 Jan; 64(1):93-8. PubMed ID: 16408454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial effects of addition of oral spray insulin (Oralin) on insulin secretion and metabolic control in subjects with type 2 diabetes mellitus suboptimally controlled on oral hypoglycemic agents.
    Guevara-Aguirre J; Guevara M; Saavedra J; Mihic M; Modi P
    Diabetes Technol Ther; 2004 Feb; 6(1):1-8. PubMed ID: 15000763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Before oral agents fail: the case for starting insulin early.
    Marre M
    Int J Obes Relat Metab Disord; 2002 Sep; 26 Suppl 3():S25-30. PubMed ID: 12174320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review of adherence with medications for diabetes.
    Cramer JA
    Diabetes Care; 2004 May; 27(5):1218-24. PubMed ID: 15111553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral hypoglycaemic agents: the first thirty years.
    Nabarro JD
    J R Coll Physicians Lond; 1992 Jan; 26(1):50-5. PubMed ID: 1573584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quality of life in patients with type 2 diabetes after switching to insulin degludec: results from a cross-sectional survey.
    Uzoigwe C; Radin M; Hamersky CM; DeKoven M; Holt C; Karkare S; Polonsky WH
    Qual Life Res; 2021 Jun; 30(6):1629-1640. PubMed ID: 33550540
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of depression on utilization patterns of oral hypoglycemic agents in patients newly diagnosed with type 2 diabetes mellitus: a retrospective cohort analysis.
    Kalsekar ID; Madhavan SS; Amonkar MM; Douglas SM; Makela E; Elswick BL; Scott V
    Clin Ther; 2006 Feb; 28(2):306-18. PubMed ID: 16678652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Studying the Hurdles of Insulin Prescription (SHIP): development, scoring and initial validation of a new self-administered questionnaire.
    Martinez L; Consoli SM; Monnier L; Simon D; Wong O; Yomtov B; Guéron B; Benmedjahed K; Guillemin I; Arnould B
    Health Qual Life Outcomes; 2007 Aug; 5():53. PubMed ID: 17727695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient-reported outcomes in transition from high-dose U-100 insulin to human regular U-500 insulin in severely insulin-resistant patients with type 2 diabetes: analysis of a randomized clinical trial.
    Kabul S; Hood RC; Duan R; DeLozier AM; Settles J
    Health Qual Life Outcomes; 2016 Sep; 14(1):139. PubMed ID: 27716283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving glycaemic control with current therapies.
    Birkeland KI
    Diabet Med; 1998; 15 Suppl 4():S13-9. PubMed ID: 9868986
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Perceived difficulties among primary care physicians for the prescription of insulin for diabetic patients].
    Lenz Alcayaga R; Ramírez J; Gac R; Lorca E
    Rev Med Chil; 2010 Mar; 138(3):281-8. PubMed ID: 20556329
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of life in type 2 diabetes mellitus patients requiring insulin treatment in Buenos Aires, Argentina: a cross-sectional study.
    Pichon-Riviere A; Irazola V; Beratarrechea A; Alcaraz A; Carrara C
    Int J Health Policy Manag; 2015 Apr; 4(7):475-80. PubMed ID: 26188812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of hypoglycemic therapeutics and nutritional supplementation for type 2 diabetes mellitus management: An insight on molecular approaches.
    Prasathkumar M; Becky R; Anisha S; Dhrisya C; Sadhasivam S
    Biotechnol Lett; 2022 Feb; 44(2):203-238. PubMed ID: 35119572
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.